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Placebo and nocebo effects are, respectively, the helpful and harmful treatment effects 
that do not arise from active treatment components. These effects have thus far been 
researched most often in pain. It is not yet clear to what extent these findings from pain can 
be generalized to other somatic symptoms. This review investigates placebo and nocebo 
effects in four other highly prevalent symptoms: dyspnea, fatigue, nausea, and itch. The 
role of learning mechanisms (verbal suggestions, conditioning) in placebo and nocebo 
effects on various outcomes (self-reported, behavioral, and physiological) of these different 
somatic symptoms is explored. A search of experimental studies indicated that, as in 
pain, the combination of verbal suggestion and conditioning is generally more effective 
than suggestion alone for evoking placebo and nocebo effects. However, conditioning 
appears more and verbal suggestions less relevant in symptoms other than pain, with 
the exception of placebo effects on fatigue and nocebo effects on itch. Physiological 
measures, such as heart rate, lung function, or gastric activity, are rarely affected even 
when self-reported symptoms are. Neurobiological correlates are rarely investigated, and 
few commonalities appear across symptoms. Expectations generally predict placebo 
and nocebo effects for dyspnea and itch but seem less involved in fatigue and nausea. 
Individual characteristics do not consistently predict placebo or nocebo effects across 
symptoms or studies. In sum, many conclusions deriving from placebo and nocebo 
pain studies do appear to apply to other somatic symptoms, but a number of important 
differences exist. Understanding what type of learning mechanisms for which symptom 
are most likely to trigger placebo and nocebo effects is crucial for generalizing knowledge 
for research and therapies across symptoms and can help clinicians to optimize placebo 
effects in practice.
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INTRODUCTION
The placebo effect, the positive treatment outcomes that cannot be ascribed to active treatment 
components, has evolved from a nuisance in clinical trials to a phenomenon worth studying in 
its own right. Placebo effects can influence clinical outcomes in a meaningful way (1) and, under 
optimal conditions, achieve a large magnitude (2, 3). Moreover, placebo effects occur not just 
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when a placebo is given, but can potentially enhance any active 
treatment that a patient receives (1, 4). Medical outcomes can 
be further influenced by the nocebo effect, where, instead of 
the positive effect in the case of placebo, harmful treatment side 
effects are evoked or increased, or positive treatment effects are 
reduced (5, 6).
Most of what we know about placebo and nocebo effects—
their magnitude, their working mechanisms, their physiological 
and neurological correlates—comes from the study of these 
effects in pain. There are good reasons for this, as pain is well 
studied, is the most commonly reported somatic symptom (7), 
and can greatly influence quality of life (8). Pain also has the 
advantage that it is relatively easy to manipulate and control in 
laboratory settings: it can be tuned “up” and “down” by exposing 
the participant to different levels of a noxious stimulus such as 
heat, cold, or pressure. By contrast, other somatic sensations 
generally take more time to evoke (e.g., fatigue) or tend to last for 
a time even after the stimulus is removed (e.g., itch and nausea). 
This has led to a strong research tradition of studies on placebo 
analgesia and nocebo hyperalgesia to emerge in the last century, 
using the benefit of cumulative findings in comparable research 
settings to thoroughly investigate underlying mechanisms of 
these effects.
Placebo and nocebo effects play a role not just in pain, but in 
a wide range of conditions and symptoms. The available research 
indicates that the underlying mechanisms for these effects might 
differ per symptom (9). Accordingly, similar procedures might 
lead to very different results when symptoms are very different, 
such as pain and hormone levels (10), or to more comparable 
results when symptoms are more alike, such as pain and 
itch (11). Symptoms can differ on aspects such as conscious 
accessibility, the amount of cognitive control one can exert over 
it, what physiological systems they are connected to, and the 
related conditions and possible pathophysiological pathways 
[see, e.g., Ref. (12) for a comparison of itch and pain]. All of 
these factors can influence a symptom’s susceptibility to placebo 
and nocebo effects or to learning mechanisms that cause them. 
The dominant position of pain in placebo and nocebo studies 
might give the impression that placebo and nocebo effects are 
only impactful for pain, or that they operate in other symptoms 
exactly as they do in pain. More importantly, knowing which 
findings generalize from pain to other symptoms could lead to 
more effective use of placebo and nocebo effects in both research 
and clinical practice.
While placebo and nocebo studies of symptoms other 
than pain are not as plentiful, some lines of research have 
a long history—for example, the placebo effect was studied 
in weightlifters and asthmatics in the early 1970s (13, 14). 
However, as in pain, these studies tend to focus only on a single 
symptom; there is very little comparative work that examines the 
similarities and differences between placebo and nocebo effects 
on pain and these other symptoms. The current review aims to 
help fill that gap. To facilitate the comparison with pain, we will 
focus on symptoms that share the features of being subjective, 
somatic, and commonly reported in the general population (7, 
15–17) and that have been studied in the area of placebo and 
nocebo effects: fatigue, dyspnea, nausea, and itch. We will focus 
primarily on whether the learning mechanisms that have been 
established for pain function similarly for these other symptoms, 
with the status of research for each symptom separately being 
featured in the discussion. The focus will be on verbal suggestion 
and conditioning, as other learning mechanisms (such as 
observational learning) are rarely investigated in the included 
symptoms [although see Ref. (18) for an exception]. We will first 
see whether these learning mechanisms are similarly effective 
at inducing placebo and nocebo effects on fatigue, dyspnea, 
nausea, and itch as they are at affecting pain. After discussing 
these results, we will compare the selected symptoms with pain 
in terms of possible underlying mechanisms, specifically the role 
of expectations, and individual predictors of placebo and nocebo 
responses.
SEARCH STRATEGY AND SELECTION 
CRITERIA
We searched the scientific literature for experimental research 
on placebo and nocebo effects on subjective, somatic, and 
commonly reported symptoms other than pain. The included 
symptoms (and related search terms) were as follows: fatigue 
(mental fatigue, muscle fatigue), itch (pruritus, antipruritic), 
nausea (motion sickness, emetic, antiemetic), dizziness (vertigo, 
fainting), and dyspnea (asthma). These terms were entered 
in databases PubMed, PsycINFO, and Web of Science in 
combination with search terms for placebo and nocebo effects 
(placebo effect, placebo effects, nocebo, conditioning, operant 
conditioning, classical conditioning, verbal suggestion). Only 
those studies were included that either mentioned at least one 
of the included symptoms in the suggestion given to participants 
or included at least one of these symptoms as a self-reported 
outcome after a learning procedure featuring verbal suggestion or 
conditioning. Both studies that included healthy participants and 
those drawing participants from clinical samples were included. 
Only experimental laboratory studies were considered, since 
there are many possible reasons for symptom change in clinical 
trials and it is unclear whether the change in the placebo group 
(placebo response) is actually due to the placebo (placebo effect) 
or due to other factors such as natural history [see, e.g., Ref. 4)]. 
This process resulted in no relevant studies for dizziness, and 
thus this symptom was not further considered. Further studies 
were added by examining included studies for references and 
upon expert recommendation.
To answer the question whether expectations play a role in 
placebo and nocebo effects in fatigue, dyspnea, nausea, and 
itch, those studies that have explicitly examined participants’ 
expectations were considered. To examine the question of which 
traits identify the placebo responder, the studies included based 
on the aforementioned criteria were scanned for individual 
characteristics used in moderation analyses. Only variables 
measured through questionnaires and gender were identified; 
no studies investigating, e.g., genetic factors were found. A brief 
summary of the results of included studies can be found in 
Table 1, while a detailed overview of every study is available as 
Supplemental Material.
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PLACEBO EFFECTS
In the prototypical experimental placebo analgesia study, 
participants are exposed to a painful stimulus, and then receive an 
inert treatment (the placebo) that is suggested to be an analgesic. 
This method is easily converted for use in other symptoms by 
changing the noxious stimulus; for example, instead of applying 
heat to induce pain, participants cycle on an ergometer to induce 
fatigue or sit in a rotation chair to induce nausea. The placebo 
itself is also adaptable: for instance, instead of an analgesic cream, 
a cream can be described as antiallergenic or an inert inhaler can 
be described as a bronchodilator. Some studies do not feature a 
separate inert medication, but directly suggest a change in the 
method or substance that induces the noxious sensation. For 
example, electrical stimulation can be described as very likely or 
very unlikely to cause itch.
Placebo effects can be evoked by only the verbal suggestion 
of symptom relief, but also by letting participants experience 
the reduction in stimulus intensity through a conditioning 
procedure. Meta-analyses have shown that in experimental 
studies investigating placebo mechanisms, verbal suggestions 
alone are on average rather effective at evoking placebo analgesia 
(3, 19). This analgesic placebo effect tends to be further enhanced 
when verbal suggestion and conditioning are combined (19–
21). Conditioning can also be used to evoke placebo effects by 
itself, without verbal suggestions (21–24), but this is less often 
investigated in pain and even rarer in most other symptoms 
we discuss. Other learning mechanisms, such as letting the 
participant observe the effect in another person, are also rarely 
examined. Therefore, we will discuss first the effect of only verbal 
suggestions, and then all studies using conditioning, either 
paired with verbal suggestion or used by itself. Within each of 
these categories, fatigue, dyspnea, nausea, and itch are handled 
in order.
PLACEBO EFFECTS EVOKED THROUGH 
VERBAL SUGGESTIONS
Fatigue. A substantial number of studies have investigated the 
effect of a verbal suggestion of reduced fatigue or increased 
performance (25–38). In seven of the 13 studies, participants 
report a lower sense of fatigue while performing a motor task in 
the placebo condition than in a control condition (25, 28–30, 32, 
33, 35). The lack of an effect in the remaining studies might be due 
to other factors, such as small sample size [Refs. (26, 38); 9 and 
10, respectively] or the generic wording of the suggestion [not 
specifically directed toward fatigue (31, 34) or suggesting a 50/50 
chance of placebo (27)]. Across all of the studies, participants 
also perform better; all but one study (37) find that participants 
either produced more power or continued a set performance for 
longer (26–33, 36, 38). Physiological indications of effort, such 
as blood lactate or heart rate, are often measured, but are not 
affected in most studies (28, 29, 33, 34, 38), even when the study 
found effects on fatigue or performance. A decreased readiness 
potential using EEG during repeated finger movements might 
indicate that placebo effects on fatigue and performance are 
caused by a central action in the preparatory phase of movement 
(35). Thus, overall, it seems that verbal suggestions are effective 
at reducing experienced fatigue and improving performance, 
but this is often not accompanied by the expected changes on 
physiological measures.
Dyspnea. Six studies, all using asthmatic participants, have 
investigated the placebo effect induced by a verbal suggestion 
TABLE 1 | Overview of results of included studies.
Learning mechanism Symptom Type of 
measure
Proportion 
positive results
Placebo—verbal 
suggestion
Fatigue Self-reported 7/13
Behavioral 10/11
Physiological 1/5
Dyspnea Self-reported 3/5
Behavioral -
Physiological 1/5
Nausea Self-reported 3/6
Behavioral 0/2
Physiological 0/4
Itch Self-reported 1/6
Behavioral -
Physiological 0/6
Placebo—conditioning Fatigue Self-reported 1/2
Behavioral 2/2
Physiological -
Dyspnea Self-reported -
Behavioral -
Physiological -
Nausea Self-reported 6/7
Behavioral 1/2
Physiological 1/4
Itch Self-reported 2/2
Behavioral 0/1
Physiological -
Nocebo—verbal 
suggestion
Fatigue Self-reported 1/3
Behavioral 1/2
Physiological 0/1
Dyspnea Self-reported 3/5
Behavioral -
Physiological 3/5
Nausea Self-reported 0/3
Behavioral 1/1
Physiological 0/1
Itch Self-reported 5/5
Behavioral 1/1
Physiological 2/2
Nocebo—conditioning Fatigue Self-reported 0/1
Behavioral 1/1
Physiological -
Dyspnea Self-reported 8/8
Behavioral -
Physiological 5/8
Nausea Self-reported 4/4
Behavioral 2/2
Physiological 0/1
Itch Self-reported 3/3
Behavioral 0/1
Physiological -
Positive results: studies where a significant effect was found in the direction matching 
the verbal suggestion or learning procedure.
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on dyspnea (39–44). Three of the five studies that examined 
self-reported dyspnea report a decrease in symptoms (39, 42, 
43). Participants in these studies first received a suggestion 
of bronchoconstriction (39, 42) or were denied their normal 
asthma medication (42, 43) before offering participants the 
placebo which was suggested to improve their breathing. The 
two studies that report non-significant findings on self-reported 
dyspnea (40, 44) tested the placebo without first inducing 
breathing problems. It is likely that a reduction of dyspnea is only 
expected or possible when it is clearly present in the first place. 
None of the studies found an effect on measures of lung function 
(39, 40, 42, 44), except Kemeny and colleagues (41), who did 
not examine self-reported dyspnea but found an improvement 
on airway reactivity after a placebo induction. No behavioral or 
neurological measures were collected. The tentative conclusion 
from these limited findings is that an existing feeling of dyspnea 
can be reduced by a verbal suggestion, but likely without 
accompanying physiological changes [which are themselves not 
strongly correlated to subjective asthma symptoms; see, e.g., Ref. 
(45)].
Nausea. Eight studies have examined the effect of suggestion 
of reduced nausea (46–53). Three studies show placebo effects 
on nausea experienced during a nausea-inducing activity after 
verbal suggestions (47, 48, 51), although the effect was limited to 
women in one study (51) and to men in another (48). A possible 
reason for the non-significant findings in the other studies (46, 
52, 53) is that in these studies, participants were not previously 
made familiar with the nausea-inducing task, possibly resulting 
in a low expectation of nausea that cannot be reduced further 
with placebo. Other studies have shown that suggestions of 
reduced nausea can reduce the disgust experienced when viewing 
disgusting stimuli (49, 50). With respect to behavioral outcomes, 
participants did not tolerate the nauseating stimulus for longer 
after a verbal suggestion of a ginger treatment, regardless of 
whether there was an effect on reported symptoms (51, 52). 
Similarly, no differences between the placebo and control groups 
were detected with an electrogastrogram in any study (46, 51, 
52), except for one (53), where participants who received a 
suggestion of reduced nausea actually showed more abnormal 
gastric activity. The two functional magnetic resonance imaging 
(fMRI) studies (49, 50) indicate an effect of a placebo with the 
suggestion of nausea reduction, showing decreased activity in the 
insula (particularly the left) and increased connectivity between 
the dorsomedial prefrontal cortex and the amygdala. The latter 
finding is consistent with processes of cognitive reappraisal 
of aversive stimuli, while the insula is a region associated with 
disgust and pain perception as well as pain analgesia (54–56). 
The overall pattern indicates that a placebo effect on nausea after 
verbal suggestion is found only on self-reported measures in 
some subgroups and under specific conditions.
Itch. Six recent studies have examined the effect of suggestions 
on itch (11, 34, 57–60). In most studies experienced itch was not 
successfully reduced (11, 34, 57, 59, 60), although it was in one 
study (58). All but one of the studies that did not find an effect gave 
only the suggestion, without a separate placebo (11, 59) or used a 
nonspecific suggestion (34, 60). Regardless of self-reported itch, 
none of the studies reported an effect on a physiological measure, 
be it weal size (58, 59), flare (59), skin temperature (59), heart 
rate (34), or skin conductance (34). Taken together, producing 
a placebo effect on itch seems to require more than just a verbal 
suggestion, with effects appearing only with very convincing 
suggestions or under specific circumstances.
Overall, placebo effects from a verbal suggestion do not seem 
to be as generally effective in other symptoms as they are in pain. 
The many studies showing clear effects on self-reported fatigue 
that extend to performance measures echo results on placebo 
analgesia, where verbal suggestion alone seems to be effective at 
reducing pain (3, 19). However, dyspnea, nausea, and itch were 
not reduced after a verbal suggestion in many studies, and seem 
to require certain conditions (such as specific phrasing of the 
suggestion) to be effective. Physiological correlates such as heart 
rate, lung function, or weal size show little evidence of being 
affected for any symptom.
PLACEBO EFFECTS EVOKED THROUGH 
CONDITIONING
In a conditioning procedure in a placebo study, participants can 
personally experience the beneficial effect of the placebo. This is 
generally done by modifying the intensity of the presented noxious 
stimulus, such as lowering the heat of a heat pain stimulus when a 
placebo cream is applied. While conditioning and suggestion were 
in the past sometimes seen as competing explanations of placebo 
effects, more recent perspectives (61, 62) generally consider them 
complementary, both contributing to the expectations that then 
influence the experience of noxious sensations. Note that when 
a study involves conditioning, this is almost always classical 
conditioning; while some studies into operant conditioning in the 
context of placebo and nocebo effects exist (63, 64), they are as of 
yet too rare too draw any general conclusions.
Fatigue. The combination of verbal suggestion and 
conditioning to produce a placebo effect on fatigue has been 
much less studied than the effect of verbal suggestion alone. 
Only two studies have adopted the method (31, 36). Both studies 
also include a group where only verbal suggestion was applied, 
allowing conclusions about the added effect of combining the 
methods. No effects on fatigue or perceived exhaustion were 
found in one study (31), while in the other (36), the self-report 
measure was only affected in the combined verbal suggestion 
and conditioning group, with no effect of suggestion alone. In 
both studies, participants in the combination condition showed 
larger effects on physical performance than those who only 
received a placebo and the suggestion. The study by Fiorio et al. 
(31), using transcranial magnetic stimulation, supports the 
idea that a placebo procedure influences a central mechanism 
(35), and extends these findings by suggesting that this results 
in rapid increases in excitability in the corticospinal system for 
the specific muscle involved. While low in number, these studies 
suggest greater placebo effects on fatigue and motor performance 
when verbal suggestion and conditioning were combined.
Dyspnea. We are not aware of studies using a design combining 
verbal suggestion and conditioning or using conditioning alone 
that investigated placebo effects on dyspnea.
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5 July 2019 | Volume 10 | Article 470Frontiers in Psychiatry | www.frontiersin.org
Nausea. Two studies have combined verbal suggestion 
and conditioning to evoke a placebo effect on nausea (48, 65). 
Horing et al. (65) found that a combination of suggestion and 
conditioning was effective in reducing both self-reported 
nausea symptoms as well as behavioral consequences (how 
often participants could move their head during the nauseating 
task and how long they could tolerate the task). No results were 
found on electrogastrogram measures of digestive tract activity. 
The other study (48) similarly found that self-reported nausea 
was reduced after a procedure of suggestion and conditioning, 
but noted that suggestion seemed to be only effective for men, 
while conditioning was only effective for women. Both studies 
found an effect that was more elusive in studies that only used a 
verbal suggestion, indicating that conditioning may have some 
added value in reducing nausea, but further research will have to 
elucidate to what extent and for which groups this applies.
For nausea, there is also a line of research into using 
conditioning alone, without verbal suggestion, to induce placebo 
effects. These studies use two strategies. The first is overshadowing, 
where during a learning phase the nausea-inducing stimulus 
is associated with a very salient stimulus (e.g., a strong-tasting 
beverage) which is then not present at test (66–68). Because the 
nausea is associated with the salient stimulus, the absence of the 
stimulus may reduce nausea. The other is latent inhibition, where 
participants are exposed to the environment where the nausea 
is induced several times before the nausea induction (66, 69, 
70). There, the fact that the environment is not just associated 
with nausea but also with previous neutral experiences will 
make it less nausea-inducing. These protocols have been used 
to reduce anticipatory nausea (66–69) and nocebo nausea (70). 
This seems to be generally effective (67–70), although the study 
implementing both interventions found no differences between 
the latent inhibition, overshadowing, combination, and control 
groups, and there were some indications that the latent inhibition 
intervention actually increased nausea (66). The one behavioral 
measure of rotation tolerance was not affected (69). Physiological 
results are mixed: some findings for heart rate correspond 
to self-report measures (68), but hormone measures either 
show no effect (67) or follow the unexpected effect of showing 
increased symptoms for latent inhibition (66). The results of the 
conditioning studies look promising in reducing self-reported 
anticipatory nausea and might stimulate other fields to continue 
to develop optimized conditioning procedures.
Itch. Only two studies specifically investigated the effect of 
verbal suggestion with conditioning on itch (57, 71). In both 
cases, the placebo consisted of an electrode, with the suggestion 
that it modified the intensity of the electrically-induced itch. 
The first study (57) found that only the combination of verbal 
suggestion and conditioning reduced self-reported itch, with 
either method individually not producing significant results. The 
second study (71) further indicated that this combination could 
also reverse nocebo effects on itch that had earlier been induced 
by a similar procedure. This reduced itch, however, did not 
result in reduced scratching behavior (72). While the evidence 
is limited, these studies suggest that the combination of verbal 
suggestion and conditioning is needed to successfully induce 
placebo effects on itch.
Overall, procedures that combine conditioning and verbal 
suggestion seem to more reliably induce a placebo effect on 
fatigue, nausea, and itch than those that use verbal suggestion 
alone. This aligns with results in pain (20, 21). It should be 
noted, however, that these results are based on a small number 
of studies, and more confirmatory work will still need to be 
done. One possible exception and example is the work in nausea, 
where a stronger tradition of studies has confirmed the utility of 
conditioning both with and without a verbal suggestion.
NOCEBO EFFECTS
Whereas placebo effects involve the reduction of noxious 
symptoms, nocebo effects consist of evoking or enhancing 
these symptoms. The experimental setup of a nocebo study is 
generally much like a placebo study, where a noxious agent is 
applied, and the participant learns through a verbal suggestion or 
conditioning to experience it differently. Nocebo research is still 
limited because of its relative novelty and the ethical concerns 
involved. In pain, studies have shown that nocebo effects require 
fewer learning trials than placebo effects (73) and are resistant 
to extinction (74). This would suggest more robust findings for 
nocebo studies than placebo studies. It has also been suggested 
that nocebo effects on pain might be more reliably evoked with 
just a verbal suggestion than placebo effects, making the addition 
of conditioning less necessary [(20); see also Ref. (2)]. We studied 
whether these findings also apply to fatigue, dyspnea, nausea, 
and itch.
NOCEBO EFFECTS EVOKED THROUGH 
VERBAL SUGGESTIONS
Fatigue. Three studies have investigated a nocebo effect on 
fatigue from verbal suggestion alone (25, 75, 76). One study (25) 
found that the suggestion of a fatigue-inducing drink increased 
participants’ rate of exhaustion, but did not decrease their 
performance or influence cardio-respiratory, muscle, and blood 
lactate measures, while another found the opposite result, with 
no effect on rate of exhaustion but a reduction in force output 
(76). The final study (75) did not find increased fatigue after a 
nonspecific suggestion of ultrasonic noise. This suggests that 
nocebo effects from verbal suggestion are possible for fatigue 
when the suggestion is specific enough, but more evidence is 
needed.
Dyspnea. Five studies, all using asthmatic participants, have 
investigated the nocebo effect of suggestion on dyspnea (39, 
40, 42, 44, 77). The results are relatively equivocal: two studies 
found an effect on reported symptoms (39, 77) while two others 
found no effect (40, 44) and another only found an effect in a 
subgroup of highly nervous participants (42). Similarly mixed 
results are found for lung measures, with two studies finding 
an effect (44, 77), which was not confirmed in two other studies 
(40, 42). One study additionally found an effect on a measure 
of airway inflammation (40). The evidence for nocebo effects on 
dyspnea and related lung function measures arising from verbal 
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suggestion alone is thus rather tenuous. The overall results are 
very mixed and no clear methodological trend seems to explain 
them.
Nausea. There are three studies examining nocebo effects 
from verbal suggestion on nausea (46, 75, 78). No studies found 
the hypothesized results, reporting no effect on experienced 
nausea (75, 78), an effect only in men on motion tolerance (78), 
and a reversed effect (46), where reported nausea and gastric 
tachyarrhythmia were actually lower for the nocebo group 
compared to control. The suggestions used in two of these 
studies were not optimal however, either referring generally to 
effects of ultrasonic noise (75) or to a drug that would increase 
nausea but reduce other symptoms of motion sickness (46). 
These studies suggest that verbal suggestions are not effective 
for evoking or worsening nausea, but studies using a more 
specific or unilateral suggestion may prove to be more effective 
in the future.
Itch. Five studies have investigated nocebo effects from the 
suggestion of increased itch (11, 79–82). All of them indicate 
that self-reported itch worsened after the nocebo suggestion, 
although the results were not consistent for every measure in 
one study (82). Scratching duration was also increased in one 
study in the group that received a very negative compared to 
a more neutral suggestion (81), but this also applied to the 
group receiving no information, and the difference was only 
seen in patients. The results on self-reported measures seem to 
transfer to the associated skin reactions (80), although again 
not consistently for every measure in one study (82). Napadow 
and colleagues (79) also performed fMRI analyses, finding 
increased activity in the dorsolateral prefrontal cortex, caudate, 
and intraparietal sulcus associated with nocebo itch. These areas 
responded in similar ways to an actual allergen, suggesting this 
activation may be specific for itch and not applicable to nocebo 
effects more generally. The results of these studies indicate 
that nocebo suggestions can worsen experienced itch, while 
the evidence is more mixed for behavioral and physiological 
correlates.
Overall, the studies investigating the effect of only verbal 
suggestions to induce nocebo effects are less numerous than 
the corresponding placebo studies, and do not provide enough 
evidence for solid conclusions. Only in itch are consistent nocebo 
effects seen, which may be due to the unique qualities of that 
symptom: itch is known to arise even when it is just talked about 
or observed in others [contagious itch; see Ref. (83) for a review]. 
The results for itch seem to most resemble those in pain, where 
nocebo effects seem easier to evoke than placebo effects. For 
dyspnea and nausea, the results for placebo and nocebo studies 
are both mixed, and for fatigue the results for placebo are more 
consistent than for nocebo effects.
NOCEBO EFFECTS EVOKED THROUGH 
CONDITIONING
Fatigue. We are aware of only a single study that has examined 
nocebo effects on fatigue elicited by a combination of verbal 
suggestion and conditioning (76). The results indicate no effect 
on perceived exhaustion, though this might also be due to a 
training effect emerging throughout the repeated sessions of the 
experiment. The procedure did lead to an overall reduction in 
performance, although the effect was not larger in the condition 
combining verbal suggestion and conditioning than in the verbal 
suggestion alone condition.
Dyspnea. Eight studies have investigated a nocebo effect 
on dyspnea using conditioning. Two of them combine verbal 
suggestion and conditioning [Refs. (84–86); note that the latter 
two use the same dataset), and six rely on conditioning while 
offering either no suggestion or a similar suggestion in both 
conditions (87–92). Two studies (84, 87) offer the participant 
an inhaler and are thus clearly placebo studies, while the 
others expose participants to scented air via a special breathing 
apparatus but do not offer a physical treatment that would be 
universally recognized as a placebo. All studies show an increase 
in self-reported asthma symptoms after conditioning. However, 
in some studies this increase in self-reported symptoms applied 
only under certain conditions [i.e., when the conditioning 
procedure featured an unpleasant and not a pleasant scent (89, 
91, 92)] or on some of the included measures [Ref. (87); only 
subjective airway obstruction was affected, and not feelings of 
dyspnea or hyperventilation]. Physiological measures of lung 
functioning and breathing were not affected in three studies 
(87, 88, 92) while five other studies found an effect on some 
of the included physiological outcomes (84, 85, 89–91). Many 
of these studies use healthy samples (84–86, 88–90, 92); the 
results do not differ systematically between the results of these 
studies and those where participants were asthmatics (84, 87) 
or psychosomatic patients (91). These studies together provide 
convincing evidence that a conditioning procedure can evoke 
self-reported symptoms of dyspnea, much more clearly than 
verbal suggestion alone, although the results remain somewhat 
inconsistent for physiological measures.
Nausea. Four studies have used either conditioning alone (78, 
93) or the combination of verbal suggestion and conditioning 
(70, 94) to induce nocebo effects on nausea. In all cases, self-
reported nausea was increased in participants, although one 
study (78) found the same gender pattern as in placebo nausea, 
where women responded more strongly than men to the 
conditioning procedure. The gender pattern also applied when 
considering how long participants could endure the nausea-
inducing rotation. Another study using only conditioning 
(93) found that participants consumed less of a drink that 
was associated with the rotation, but no effect on tolerance 
of rotation and also no effect on two hormonal outcomes. 
The findings indicate that gender may be an important factor 
in placebo and nocebo nausea. The combination of verbal 
suggestion and conditioning seems to be quite effective at 
influencing nausea, and more effective than suggestion alone, 
although very limited evidence suggests this might not extend 
to physiological correlates of nausea.
Itch. The three available studies indicate that the combination 
of verbal suggestion and conditioning is effective for inducing 
nocebo effects on itch (57, 71, 95). All of the available studies 
find a nocebo effect on self-reported itch when using a procedure 
combining suggestion and conditioning, although one follow-up 
Placebo and Nocebo Across SymptomsWolters et al.
7 July 2019 | Volume 10 | Article 470Frontiers in Psychiatry | www.frontiersin.org
analysis (72) did not find consistent effects on scratching 
behavior. Moreover, the study by van de Sand et al. (95) used 
fMRI to investigate neural activity associated with nocebo 
itch, finding increased activity in the rolandic operculum and 
increased connectivity between the insula and periaqueductal 
grey in the nocebo condition. These results do not correspond 
to those found in the earlier fMRI study into nocebo itch (79), 
which did not use conditioning and only tested patients. Activity 
in the operculum is also found in fMRI nocebo hyperalgesia 
studies (96), but these results do not overlap with imaging studies 
for other symptoms. While no immediate pattern emerges from 
behavioral or physiological outcomes, self-reported itch is 
clearly influenced when conditioning and verbal suggestion are 
combined.
The low number of studies on nocebo effects that use 
conditioning makes it hard to draw a conclusion across symptoms 
that is not pre-emptive. The limited results available would suggest 
that nocebo effects on dyspnea and nausea are more robust after 
the combination of verbal suggestion and conditioning than they 
are after verbal suggestion alone. The combination procedure did 
not seem to lead to more robust effects in fatigue, where results 
are limited but appear weak, or in itch, where verbal suggestion 
alone already produced clear nocebo effects. In this sense, only 
the results for itch seems to echo those on pain, where it has 
also been suggested that nocebo effects can be evoked as easily 
with suggestion alone as with a combination of suggestion and 
conditioning (20).
THE MEDIATING ROLE OF 
EXPECTANCIES
A common theoretical view is that placebo and nocebo effects 
function by means of expectancies: you will feel less pain when 
you expect to (61, 97, 98). In pain, research has shown that the 
expectation of analgesia or hyperalgesia is indeed a contributing 
factor to placebo and nocebo effects [e.g., Refs. (99–100)]. 
Current theoretical perspectives generally consider verbal 
suggestion and conditioning complementary forces that together 
influence the expectations that in turn influence the experience 
of noxious sensations (61, 62).
Fatigue. One study (25) found a strong relation between the 
expectation of increased or decreased fatigue and increases and 
decreases in performance. Other studies found an effect of the 
suggestion on participants’ expectations, but no relationship 
between expectations and fatigue (34) or performance (37).
Dyspnea. De Peuter and colleagues (84) found that participants 
undergoing a nocebo procedure had higher expectations for 
asthma symptoms as well as higher asthma symptom ratings; 
however, expectations were only statistically related for 
asthmatics and not the whole sample. From another angle, a 
study that specifically tried to not to instill any expectations in 
participants also found no effects on dyspnea (101).
Nausea. Four studies have directly investigated the role 
expectations in placebo and nocebo effects on nausea (47, 51, 
52, 70), but only one of them (47) found the hypothesized effect, 
with both expectations of nausea and self-reported nausea lower 
in the placebo than in the control group. The other studies show 
discrepancies; either expectancies were affected but nausea was 
not (52), nausea was effected but expectancies were not (51), or 
there was a relationship between expectations and nausea for 
nocebo effects but not for placebo effects (70).
Itch. The study by van Laarhoven and colleagues (11) showed 
a correlation between expected itch and nocebo-induced itch 
ratings. Another study found increased expectations but no 
corresponding effect on itch (34), while a third found a relation 
between positive expectations and reduced symptoms only in the 
experimental group (59). An investigation of the mechanisms 
behind placebo and nocebo effects on itch (102) found that 
placebo responders self-generated fewer itch expectations in a 
separate task, although corresponding results were not found for 
nocebo responders.
The available evidence points to differential effects of 
expectations for every symptom, with stronger evidence for 
expectations as a mediator in itch and some evidence in dyspnea, 
but more evidence against a mediating relationship in fatigue and 
nausea. Further research is needed to elucidate what underlying 
mechanisms might additionally play a role in placebo and nocebo 
effects in these symptoms, especially for nausea and fatigue 
where expectations might not play an important role. Other 
mechanisms such as attention and fear have been suggested [e.g., 
Refs. (103, 104)], but have only been investigated infrequently, 
especially outside of pain.
IDENTIFYING THE PLACEBO RESPONDER
The question whether it is possible to recognize the placebo 
responder is almost as old as the study of placebo effects itself 
(105), but consistent findings have been elusive (106). One 
possible reason for the lack of consistent findings could be that 
predictors are different for different symptoms. We therefore 
review the findings from the included studies for each of the 
discussed symptoms.
Fatigue. The only study that investigated outcomes on fatigue 
as well as individual characteristics (34) found no moderating 
effect of neuroticism, extraversion, positive or negative affectivity, 
depression, anxiety, catastrophizing, or body vigilance.
Dyspnea. Based on a fear learning model (107), it has been 
hypothesized that participants high in negative affectivity 
might respond more strongly to negative suggestions of 
impaired breathing. This has been examined in several studies, 
with three finding the expected relationship (42, 87, 88) but 
four others no relationship (41, 89, 91) or an effect only for 
one of six subjective breathing measures (84). Suggestibility 
has also been examined as a possible predictor, with one study 
finding a relationship (77) that was not confirmed in three 
other studies (39, 41, 42). Likewise, no effect was found in 
one study for positivity (41). A final study (91) found no effect 
for information seeking and a negative effect of a blunting 
behavioral style.
Nausea. Two studies investigated the relationship between 
a placebo effect and multiple individual characteristics. One 
found a larger placebo effect for participants with lower scores 
Placebo and Nocebo Across SymptomsWolters et al.
8 July 2019 | Volume 10 | Article 470Frontiers in Psychiatry | www.frontiersin.org
on general self-efficacy, internal locus of control, generalized 
self, and mobility of nervous processes (108), while the other 
found no effect of the same variables as well as no effect of 
anxiety or optimism (51). As mentioned before, in other studies 
an effect is seen for gender, with men showing larger effects 
on placebo and nocebo nausea after suggestion and women 
showing larger effects after conditioning (48, 78), although one 
study also found suggestion effective only in women (51). There 
is some indication that this effect may be due to the gender of 
the experimenter (52).
Itch. Several studies in itch have examined many individual 
characteristics, but found almost no effects for any of them, 
regardless of whether they found actual placebo or nocebo 
effects (11, 34, 57, 71). The variables investigated in these studies 
are theorized to relate to expectations and include neuroticism, 
extraversion, positive and negative affectivity, depression, 
anxiety, catastrophizing, body vigilance, optimism, hope, 
worrying, impulsivity, self-efficacy, general future expectations, 
suggestibility, and social desirability characteristics. The only 
one of these studies to find effects (57) did so only in the group 
where conditioning and verbal suggestion were combined, which 
was also the only condition that showed effects. Here, a greater 
placebo effect was associated with less hope, while greater nocebo 
effects were associated with less hope and extraversion and more 
worrying, and negative effect. Another study investigating fewer 
variables (109) found a positive relationship between a placebo 
effect and ego resiliency but none with neuroticism. Considering 
the many variables investigated across these studies, the few 
observed associations should be interpreted with care.
Taken together, these results suggest that individual 
characteristics do not consistently predict placebo or nocebo 
effects on fatigue, dyspnea, nausea, and itch. The search for 
predictors is inconvenienced by the fact that different studies 
tend to investigate different variables and many results still 
need to be replicated. It should also be noted that, compared 
to some other symptoms, the type of variables under 
consideration is rather narrow, being almost entirely limited 
to personality factors. Other placebo and nocebo studies have, 
for example, found indications of genetic predispositions 
(110) or neurochemical indicators (9). Since placebo effects 
seem to be determined by a variety of different factors (social, 
psychological, neurobiological, genetic), future studies may 
need to incorporate more sophisticated statistical methods to 
test the combined effect of several predictors at once in order 
to identify the placebo responder [for some recent examples in 
pain, see, e.g., Refs. (111, 112)].
DISCUSSION
This review investigated to what extent findings from studies on 
placebo analgesia and nocebo hyperalgesia also apply to fatigue, 
dyspnea, nausea, and itch. Broad similarities can be observed in 
that placebo and nocebo effects are evoked for these symptoms 
in a large proportion of studies using similar methods. Some 
specific results also appear to be consistent: placebo effects 
are more likely after a procedure combining conditioning and 
verbal suggestion than verbal suggestion alone, and there is no 
clear evidence which individual characteristics predict who will 
respond to placebo and who will not. Other findings do not 
clearly confirm those in pain. We find little evidence that verbal 
suggestion alone can consistently evoke placebo and nocebo 
effects across symptoms, with the exception of placebo effects 
on fatigue and nocebo effects on itch. For dyspnea and nausea 
only, nocebo effects seem to be larger after a combination of 
verbal suggestion and conditioning than suggestion alone. There 
is some evidence for a mediating role of expectations in placebo 
and nocebo effects across symptoms, although to a lesser extent 
in nausea or fatigue. Altogether, it seems that placebo and 
nocebo studies on pain provide a reasonable starting point for 
predicting these effects in other sensations, but a number of 
differences caution against extrapolating every finding in pain 
to other symptoms.
Each of the sensations we discuss has been studied in a line of 
research separated from the others, each with its own strengths 
and opportunities for further inquiry. Studies that examine 
fatigue tend to come from the field of sport psychology, and 
therefore focus on improving athletic performance. This has led 
to placebo effects being investigated much more than nocebo 
effects. Performance is generally the primary outcome, with 
perceived exhaustion as just one extra variable. Participants 
in these studies are generally physically active individuals, 
sometimes even professional athletes. These factors obviously 
limit the generalizability of these findings to medical contexts, 
where fatigue is a large problem (113); it remains to be seen to 
what extent the findings apply to patients suffering from chronic 
or mental fatigue. In the context of improving performance, 
investigating mechanisms behind the effect is perhaps a secondary 
concern, and fewer studies examine the effect of conditioning 
or individual characteristics that predict the response. Several 
researchers have, however, started the work of performing tightly 
controlled experimental studies that offer more insight into the 
exact mechanisms of placebo and nocebo effects on fatigue [e.g., 
Refs. (31, 76)]. It would be fruitful to extend these toward the 
clinical domain, especially since two separate trials have already 
shown patients suffering from fatigue can benefit from a placebo 
intervention (114, 115).
In dyspnea, there is a strong clinical focus, since the background 
of many of these studies comes from the study and treatment of 
asthma and somatic symptom disorders. A large proportion of 
studies therefore also uses asthmatics as participants. This, in turn, 
also limits generalizability for some findings, albeit in another 
direction than in the case of fatigue. Since this field features 
older studies, it also shows more methodological limitations, 
such as low participant numbers, nonspecific suggestions, and 
unclear symptom induction methods that can easily be rectified 
in new studies. Studies that include both conditioning and verbal 
suggestion, allowing the effects to be compared, would also be 
a valuable addition. A perhaps bigger issue is that no research 
group seems to have focused specifically on placebo and nocebo 
effects in dyspnea. This has led to a lack of common methods and 
conceptualizations that would facilitate comparisons within the 
subdiscipline and to other subdisciplines, despite having one of 
the longest traditions of placebo research [reaching as far back 
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as the study in Ref. (116)]. This might be helped by systematic 
review or meta-analysis, of the type that exists for other fields 
[e.g., Refs. (117, 118)].
A clear experimental tradition exists in placebo and nocebo 
effects on nausea. The field originated in the study of anticipatory 
nausea in chemotherapy (68, 119), so it has a clear clinical angle, 
even though later studies focus on healthy participants. The 
subdiscipline also sports two dedicated research groups and 
insightful reviews (118, 119). A strong theoretical foundation in 
conditioning has not only improved upon mixed initial results (46, 
52) but has also led to the development of the latent inhibition and 
overshadowing paradigms that are, as of yet, rarely applied in the 
rest of the placebo literature. We echo earlier calls (120) that these 
results should be replicated and applied to other fields of placebo 
research. This subdiscipline also offers conclusions that deviate 
the most from findings in pain, with an increased importance 
of gender [(48, 51, 78); see also Ref. (121) for a recent nuanced 
overview] and indications of a reduced role of expectations 
(51, 52, 70). The latter finding is further confirmed by findings 
in clinical trials that report similarly inconsistent results when 
expectations are explicitly investigated (122, 123). Our findings 
do appear to fit with earlier speculation that the gustatory system 
may have a special capability for unconscious conditioning (124). 
Due to its connection with the digestive system, nausea may have 
more in common with symptoms like hormone levels that are 
more affected by unconscious conditioning than consciously 
accessible expectations (10). However, since pain is also affected 
by implicit conditioning (125), further comparisons are needed 
to resolve this question.
Most studies of placebo and nocebo effects on itch are 
comparatively recent. This has allowed the field to benefit from 
advances in other subdisciplines, and thus the studies cover 
different methods and avoid some of the limitations of earlier 
work. Itch studies also feature a large number of individual 
variables as possible moderators, although no consistent 
findings have emerged. This may be taken as an indication that 
individual predictors, at least of the kind that can be measured 
by questionnaires, might not provide much further insight in 
experimental studies of placebo and nocebo effects. Several 
studies in the field have also investigated effects arising from 
verbal suggestion without a physical placebo (11, 59, 80–82), 
one of which also forgoes deception (59). These are interesting 
explorations of alternative applications of placebo effects that 
can also be considered in other subdisciplines. Although the 
two fMRI studies of nocebo itch do not report clearly congruous 
results, this is an important first step in investigating whether 
there is a common nocebo network across symptoms.
Aside from pain, fatigue, dyspnea, nausea, and itch, many 
other symptoms exist that can be affected by placebo and 
nocebo effects. Results indicate effects on variables as varied as 
sleep quality (126), symptoms of Parkinson disease (10), and 
depression (9). The current review was limited to sensations 
that share several important similarities with pain, but the 
question of generalizability of course applies to other sensations 
as well. Comparisons between these other symptoms can also 
answer important questions about underlying mechanisms and 
predictors that cannot be answered for the included symptoms 
in this review. For example, the neurological underpinnings of 
placebo effects in Parkinson disease have been studied more 
(9) than similar mechanisms in dyspnea or nausea. Similarly, 
there are studies of genetic predictors of placebo effects on pain 
(127) and fatigue (115), but the available research does not 
allow a comparison of genetic predictors between the symptoms 
included in this review. Comparisons might also be valuable for 
predictors with clear implications for clinical practice, such as 
the perceived cost of the placebo (128, 129), the odds of receiving 
placebo (51, 130), the invasiveness of the placebo (131, 132), 
other interventions that could enhance the effect of placebos 
(133), or pre-existing associations that could influence symptom 
acquisition [e.g., the color red being associated with pain (134)].
In order to translate findings to clinical practice, a comparison 
must also be made between healthy and patient populations. The 
included studies mostly use healthy volunteers as participants, 
but a reasonable number focus on patients. While the number of 
studies that compare healthy and patient populations is too low 
for a meaningful analysis, there is some indication that patients 
show different or stronger results (79, 81, 84). A meta-analysis of 
placebo-like effects on pain in patients (99) tentatively indicated 
that effects on chronic pain are smaller than on experimentally 
induced or acute procedural pain, possibly because of a relatively 
high number of unsuccessful treatment experiences in chronic pain 
patients. These same experiences, however, should theoretically 
increase the likelihood of nocebo effects. This is especially relevant 
considering multiple theories that argue that certain chronic 
conditions may be exacerbated by or find their etiology in learning 
effects (107, 135, 136). These theories focus on sensitization, fear 
learning, conditioning, and generalization, which all likely play a 
role in nocebo effects. More research that compares healthy groups 
to those suffering chronically from the relevant symptoms or 
investigates the progression of these chronic complaints is sorely 
needed to indicate how much support there is for these theories. 
This would allow knowledge of placebo and nocebo effects to be 
utilized to prevent the development and aid the treatment of chronic 
conditions, such as by counterconditioning the nocebo effect (71).
Our conclusions are limited by the small number of studies 
available. More studies are needed for solid conclusions, especially 
about nocebo effects and the added value of combining verbal 
suggestions with conditioning. Many of the included studies 
include methodological limitations, such as a small sample size, 
the omission of a baseline measure, ineffective induction of 
noxious sensation, or a less convincing verbal suggestion. The 
included studies also show a large amount of heterogeneity in 
terms of the methods they use to induce noxious sensations or 
evoke placebo and nocebo effects. Lastly, the lack of a systematic 
approach means the review is not exhaustive.
In conclusion, learning mechanisms of placebo and nocebo 
effects show large overlap, but also important differences across 
pain, fatigue, dyspnea, nausea, and itch. Knowledge of these 
differences can be used to optimally control these effects in 
experimental and clinical studies and increase placebo and reduce 
nocebo effects in clinical practice. As the separate subdisciplines 
for each symptom not only provide different results, but also 
differ in the amount and type of studies available, this review also 
highlights future promising research possibilities.
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